Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13011271 | 0.87 | ROCK2 (0.51) | CCR2ROCK2HDAC6HDAC8HDAC1 | |
| SCHEMBL13011676 | 0.85 | ROCK2 (0.45) | CCR2ROCK2HDAC6HDAC8HDAC1 | |
| SCHEMBL28039674 | 0.85 | CYP19A1 (0.64) | CCR2FOLH1HDAC6FABP4HDAC1 | |
| SCHEMBL13011551 | 0.83 | FOLH1 (0.56) | CCR2FOLH1HDAC6FABP4HDAC1 | |
| SCHEMBL23789536 | 0.80 | CYP19A1 (0.64) | CCR2HDAC6HDAC8HDAC1CYP19A1 | |
| SCHEMBL13062129 | 0.79 | HCAR3 (0.55) | CCR2FOLH1ROCK2HDAC6FABP4 | |
| SCHEMBL13011549 | 0.79 | FOLH1 (0.50) | CCR2FOLH1HDAC6FABP4HDAC1 | |
| SCHEMBL5439956 | 0.77 | FABP4 (0.43) | CCR2ROCK2HDAC6HDAC8FABP4 | |
| SCHEMBL16093881 | 0.77 | ALDH1A1 (0.68) | FOLH1HDAC6FABP4HDAC1CYP19A1 | |
| SCHEMBL6432749 | 0.77 | CCR2 (0.62) | CCR2HDAC6HDAC8FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2119704-A1 | ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | HTR5A, GRM5, HTR1E | CCR2 3555/4885FOLH1 1213/4885ROCK2 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.